MA53898A - Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament - Google Patents
Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicamentInfo
- Publication number
- MA53898A MA53898A MA053898A MA53898A MA53898A MA 53898 A MA53898 A MA 53898A MA 053898 A MA053898 A MA 053898A MA 53898 A MA53898 A MA 53898A MA 53898 A MA53898 A MA 53898A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazin
- ylmethyl
- medicines
- morpholine derivatives
- morpholine
- Prior art date
Links
- JKLJHSTZIZURSR-UHFFFAOYSA-N 4-(pyrazin-2-ylmethyl)morpholine Chemical class C=1N=CC=NC=1CN1CCOCC1 JKLJHSTZIZURSR-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200943 | 2018-10-17 | ||
| PCT/EP2019/078027 WO2020079039A1 (fr) | 2018-10-17 | 2019-10-16 | Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation en tant que médicament |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53898A true MA53898A (fr) | 2022-01-26 |
| MA53898B1 MA53898B1 (fr) | 2023-03-31 |
Family
ID=63878518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53898A MA53898B1 (fr) | 2018-10-17 | 2019-10-16 | Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11166958B2 (fr) |
| EP (1) | EP3867244B1 (fr) |
| JP (1) | JP7093468B2 (fr) |
| KR (1) | KR20210079325A (fr) |
| CN (1) | CN112888685B (fr) |
| AR (1) | AR116711A1 (fr) |
| AU (1) | AU2019362330B2 (fr) |
| BR (1) | BR112021004993A2 (fr) |
| CA (1) | CA3113308A1 (fr) |
| CL (1) | CL2021000858A1 (fr) |
| CO (1) | CO2021004612A2 (fr) |
| CR (1) | CR20210184A (fr) |
| DK (1) | DK3867244T3 (fr) |
| DO (1) | DOP2021000069A (fr) |
| EA (1) | EA202191014A1 (fr) |
| EC (1) | ECSP21027009A (fr) |
| ES (1) | ES2940184T3 (fr) |
| FI (1) | FI3867244T3 (fr) |
| HR (1) | HRP20230249T1 (fr) |
| HU (1) | HUE061891T2 (fr) |
| IL (1) | IL282142B2 (fr) |
| JO (1) | JOP20210075A1 (fr) |
| LT (1) | LT3867244T (fr) |
| MA (1) | MA53898B1 (fr) |
| MX (1) | MX2021004418A (fr) |
| PE (1) | PE20211278A1 (fr) |
| PH (1) | PH12021550834A1 (fr) |
| PL (1) | PL3867244T3 (fr) |
| PT (1) | PT3867244T (fr) |
| RS (1) | RS63988B1 (fr) |
| SA (1) | SA521421756B1 (fr) |
| SG (1) | SG11202103806VA (fr) |
| SI (1) | SI3867244T1 (fr) |
| TW (1) | TWI828779B (fr) |
| WO (1) | WO2020079039A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980401A1 (fr) * | 2019-06-04 | 2022-04-13 | Boehringer Ingelheim International GmbH | Dérivés de purine, utilisés en tant que modulateurs négatifs de nr2b et leur utilisation en tant que médicament, en particulier pour le traitement de troubles dépressifs |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
| WO2002080928A1 (fr) * | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | Antagonistes de nmda/nr2b nonaryl-heterocyclo amidyle n-substitues |
| PL216636B1 (pl) * | 2001-07-24 | 2014-04-30 | Richter Gedeon Vegyészeti Gyár RT | Pochodne amidów kwasów karboksylowych, środek farmaceutyczny, sposób wytwarzania pochodnych amidów kwasów karboksylowych, sposób wytwarzania środka farmaceutycznego i zastosowanie pochodnych amidów kwasów karboksylowych |
| EP1959959B1 (fr) * | 2005-12-06 | 2013-04-10 | Merck Sharp & Dohme Corp. | Antagonistes de recepteur de prokineticine de morpholine-carboxamide |
| WO2010088414A2 (fr) * | 2009-01-28 | 2010-08-05 | Emory University | Potentialisateurs du récepteur nmda, sélectifs pour des sous-unités, et destinés au traitement d'états neurologiques |
| WO2012128582A2 (fr) * | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant |
| EA025667B1 (ru) | 2012-10-18 | 2017-01-30 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ АКТИВНОСТИ РЕЦЕПТОРА mGluR5 |
| JP6577479B2 (ja) * | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
| US10913736B2 (en) | 2014-08-22 | 2021-02-09 | University Of Washington | Specific inhibitors of methionyl-tRNA synthetase |
| EP3362447B1 (fr) * | 2015-10-14 | 2020-08-26 | Bristol-Myers Squibb Company | Antagonists nr2b sélectifs |
-
2019
- 2019-10-16 HU HUE19786343A patent/HUE061891T2/hu unknown
- 2019-10-16 PL PL19786343.4T patent/PL3867244T3/pl unknown
- 2019-10-16 CR CR20210184A patent/CR20210184A/es unknown
- 2019-10-16 MA MA53898A patent/MA53898B1/fr unknown
- 2019-10-16 CN CN201980067936.7A patent/CN112888685B/zh active Active
- 2019-10-16 PE PE2021000513A patent/PE20211278A1/es unknown
- 2019-10-16 KR KR1020217014924A patent/KR20210079325A/ko unknown
- 2019-10-16 CA CA3113308A patent/CA3113308A1/fr active Pending
- 2019-10-16 JO JOP/2021/0075A patent/JOP20210075A1/ar unknown
- 2019-10-16 SG SG11202103806VA patent/SG11202103806VA/en unknown
- 2019-10-16 SI SI201930465T patent/SI3867244T1/sl unknown
- 2019-10-16 AR ARP190102937A patent/AR116711A1/es unknown
- 2019-10-16 JP JP2021520981A patent/JP7093468B2/ja active Active
- 2019-10-16 HR HRP20230249TT patent/HRP20230249T1/hr unknown
- 2019-10-16 FI FIEP19786343.4T patent/FI3867244T3/fi active
- 2019-10-16 BR BR112021004993-2A patent/BR112021004993A2/pt unknown
- 2019-10-16 MX MX2021004418A patent/MX2021004418A/es unknown
- 2019-10-16 EP EP19786343.4A patent/EP3867244B1/fr active Active
- 2019-10-16 PT PT197863434T patent/PT3867244T/pt unknown
- 2019-10-16 EA EA202191014A patent/EA202191014A1/ru unknown
- 2019-10-16 ES ES19786343T patent/ES2940184T3/es active Active
- 2019-10-16 WO PCT/EP2019/078027 patent/WO2020079039A1/fr active Application Filing
- 2019-10-16 DK DK19786343.4T patent/DK3867244T3/da active
- 2019-10-16 TW TW108137247A patent/TWI828779B/zh active
- 2019-10-16 RS RS20230140A patent/RS63988B1/sr unknown
- 2019-10-16 IL IL282142A patent/IL282142B2/en unknown
- 2019-10-16 AU AU2019362330A patent/AU2019362330B2/en active Active
- 2019-10-16 US US16/654,030 patent/US11166958B2/en active Active
- 2019-10-16 LT LTEPPCT/EP2019/078027T patent/LT3867244T/lt unknown
-
2021
- 2021-04-07 CL CL2021000858A patent/CL2021000858A1/es unknown
- 2021-04-13 CO CONC2021/0004612A patent/CO2021004612A2/es unknown
- 2021-04-14 PH PH12021550834A patent/PH12021550834A1/en unknown
- 2021-04-14 SA SA521421756A patent/SA521421756B1/ar unknown
- 2021-04-16 EC ECSENADI202127009A patent/ECSP21027009A/es unknown
- 2021-04-16 DO DO2021000069A patent/DOP2021000069A/es unknown
- 2021-08-27 US US17/458,631 patent/US20210393644A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52421A (fr) | Composés pharmaceutiques | |
| MA44075A (fr) | Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1 | |
| MA54714A (fr) | Formulation de nicotine | |
| CL2018000542A1 (es) | Nuevos derivados de fenoximetilo. | |
| MA44225A (fr) | Sulfonylurées et composés apparentés et leur utilisation | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| MA45613A (fr) | Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| MA56183A (fr) | Pyrazolo-pyridines hétéroaromatiques substituées et leur utilisation en tant que modulateurs du récepteur glun2b | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| DK3258938T3 (da) | Phenothiazinanaloger som mitokondrie terapeutiske midler | |
| MA43705A (fr) | Formulation pharmaceutique | |
| MA44987A (fr) | Formulations de médicaments améliorées | |
| MA45187A (fr) | Combinaisons pharmaceutiques | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| MA47516A (fr) | Composition pharmaceutique | |
| DK3870234T3 (da) | Antistoflægemiddelkonjugater omfattende ecteinascidinderivater | |
| GT201600252A (es) | Derivados de naftiridinadiona | |
| DK3666787T3 (da) | Antistoflægemiddelkonjugater som inkluderer hemiasterlinderivat | |
| MA40524A (fr) | Dérivés d'adrénomédulline stabilisés et leur utilisation |